Last reviewed · How we verify
NCT06908876
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
Phase 2 trial testing IBI302 in Diabetic Macular Oedema in 150 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Innovent Biologics Technology Limited (Shanghai R&D Center) |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 24 April 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 28 February 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- IBI302
- IBI302
- Faricimab (FARICIMAB) — full drug profile →
Conditions studied
- Diabetic Macular Oedema — all drugs for Diabetic Macular Oedema →
Sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center) — full company profile →
Who can join
Adults 18 to 80, any sex, with Diabetic Macular Oedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06908876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IBI302
Trials testing the same drug.
- NCT05972473 — A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD · Phase 3 · active not recruiting
- NCT03814291 — A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration · Phase 1 · completed
Other Innovent Biologics Technology Limited (Shanghai R&D Center) trials
Trials by the same sponsor.
- NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout · Phase 3 · recruiting
- NCT07327632 — This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
- NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting
- NCT07160400 — A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06908876 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics Technology Limited (Shanghai R&D Center)
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing